Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Baricitinib

FDA-approved product (tablet, oral), marketed as Baricitinib, Olumiant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Baricitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Baricitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Baricitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • JAK Signaling in Depression and Cognition in Male Football Players

    NCT07608796 · start 2026-09

    Registered record
    Registry ID
    NCT07608796
    Conditions
    Depressive Symptoms; Cognitive Symptom
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2027-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Symptoms; Cognitive Symptom
    InterventionBaricitinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

    NCT06381661 · start 2026-07-09

    Registered record
    Registry ID
    NCT06381661
    Conditions
    Sepsis
    Interventions
    Tocilizumab; Baricitinib; Anakinra; Hydrocortisone; Hydrocortisone and fludrocortisone; Heparin; Low molecular weight heparin; Recombinant humanThrombomodulin( rhTM); Sivelestat; Usual care; blood purification with MTx.100 Plasma Adsorption Column; G-CSF filgrastim; Interferon gamma-1b; Fludrocortisone; Prophylactic unfractionated heparin (UFH); Octaplas LG; Plasminogen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-09
    Completion
    2031-07-09
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionTocilizumab; Baricitinib; Anakinra; Hydrocortisone +13 more
    PhasePhase 2
    Registry statusRecruiting

  • TPO-RA Plus Baricitinib vs. TPO-RA for ITP

    NCT07669675 · start 2026-07-01

    Registered record
    Registry ID
    NCT07669675
    Conditions
    ITP - Immune Thrombocytopenia
    Interventions
    Baricitinib; TPO-RA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2028-08-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionITP - Immune Thrombocytopenia
    InterventionBaricitinib; TPO-RA
    PhasePhase 2
    Registry statusNot yet recruiting

  • Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

    NCT07081763 · start 2026-05

    Registered record
    Registry ID
    NCT07081763
    Conditions
    HIV-1-infection
    Interventions
    Baricitinib 2 MG; Sirolimus 2 MG; Placebo of baricitinib 2 MG; Placebo of sirolimus 2 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2030-11
    Enrolment
    191

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionBaricitinib 2 MG; Sirolimus 2 MG; Placebo of baricitinib 2 MG; Placebo of sirolimus 2 MG
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

    NCT07491016 · start 2026-03-01

    Registered record
    Registry ID
    NCT07491016
    Conditions
    Telitacicept; Treatment Compliance; Rheumatoid Arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-03-01
    Completion
    2028-03-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTelitacicept; Treatment Compliance; Rheumatoid Arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

    NCT06923072 · start 2026-02-18

    Registered record
    Registry ID
    NCT06923072
    Conditions
    Kohlmeier-Degos Disease; Malignant Atrophic Papulosis; Degos Disease; Papulosis, Malignant Atrophic
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-02-18
    Completion
    2030-12-15
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKohlmeier-Degos Disease; Malignant Atrophic Papulosis; Degos Disease; Papulosis, Malignant Atrophic
    InterventionBaricitinib
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

    NCT07222137 · start 2026-01-12

    Registered record
    Registry ID
    NCT07222137
    Conditions
    Diabetes Mellitus, Type 1
    Interventions
    Baricitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-12
    Completion
    2031-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1
    InterventionBaricitinib; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

    NCT06977035 · start 2025-05-05

    Registered record
    Registry ID
    NCT06977035
    Conditions
    Rheumatoid Arthritis
    Interventions
    Nerve Conduction Study
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2026-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionNerve Conduction Study
    PhaseNot applicable
    Registry statusRecruiting

  • Baricitinib for Patients With Intracerebral Hemorrhage

    NCT06737705 · start 2025-01-01

    Registered record
    Registry ID
    NCT06737705
    Conditions
    Intracerebral Hemorrhage
    Interventions
    Baritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-08-18
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracerebral Hemorrhage
    InterventionBaritinib
    PhasePhase 2
    Registry statusCompleted

  • A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

    NCT06490757 · start 2024-10-02

    Registered record
    Registry ID
    NCT06490757
    Conditions
    Inflammatory Hepatocellular Adenoma
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-02
    Completion
    2028-09-02
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Hepatocellular Adenoma
    InterventionBaricitinib
    PhasePhase 2
    Registry statusRecruiting

  • Vitiligo, New Treatment and Serum s100B

    NCT06768840 · start 2024-10-02

    Registered record
    Registry ID
    NCT06768840
    Conditions
    Vitiligo, Generalized
    Interventions
    Baricitinib; oral mini pulse; Narrow Band UVB Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2024-10-02
    Completion
    2025-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo, Generalized
    InterventionBaricitinib; oral mini pulse; Narrow Band UVB Treatment
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

    NCT06240351 · start 2024-04-22

    Registered record
    Registry ID
    NCT06240351
    Conditions
    Frontal Fibrosing Alopecia
    Interventions
    Baricitinib 4 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-04-22
    Completion
    2027-09-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFrontal Fibrosing Alopecia
    InterventionBaricitinib 4 MG Oral Tablet
    PhasePhase 4
    Registry statusActive not recruiting

  • Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

    NCT06158113 · start 2024-03-13

    Registered record
    Registry ID
    NCT06158113
    Conditions
    Lichen Planus, Oral; Lichen Planus, Mucosal; Oral Lichen Planus
    Interventions
    Baricitinib 4 milligram Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-03-13
    Completion
    2026-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Planus, Oral; Lichen Planus, Mucosal; Oral Lichen Planus
    InterventionBaricitinib 4 milligram Oral Tablet
    PhasePhase 2
    Registry statusActive not recruiting

  • "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

    NCT05914584 · start 2023-07-01

    Registered record
    Registry ID
    NCT05914584
    Conditions
    Hospital-acquired Pneumonia
    Interventions
    Baricitinib 4 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-07-01
    Completion
    2025-12-31
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-acquired Pneumonia
    InterventionBaricitinib 4 MG
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

    NCT05852847 · start 2023-05-16

    Registered record
    Registry ID
    NCT05852847
    Conditions
    Immune Thrombocytopenia
    Interventions
    Baricitinib 2 MG [Olumiant]; Danazol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-05-16
    Completion
    2025-05
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenia
    InterventionBaricitinib 2 MG [Olumiant]; Danazol
    PhasePhase 2
    Registry statusUnknown